Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine
Launched by MAHIDOL UNIVERSITY · Aug 10, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
The study design was a prospective interventional case series. Our institutional ethical committee approved the study protocol in April 2004. We performed this study between July 2004 and December 2009. During this period, there were 2 episodes of EKC epidemic. The first episode was in 2006 and the second in 2009.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients who were diagnosed with EKC at the outpatient ophthalmic unit
- Exclusion Criteria:
- • children younger than six years
- • women being pregnant or during lactation
- • history of allergy to povidone-iodine
- • prior ocular surgery
- • contact lens usage and chronic eye diseases with current eye medications.
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkoknoi, Bangkok, Thailand
Patients applied
Trial Officials
Adisak Trinavarat, MD
Principal Investigator
Siriraj Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials